F2G Ltd has raised $70 million in venture capital finance to advance its antifungal agent, olorofim, which has shown promise in treating invasive Aspergillosis, a fungal infection affecting high-risk immunosuppressed populations. Olorofim is completing a Phase 2b study and poised to start Phase 3. It has already received a breakthrough therapy designation from the Food and Drug Administration and plans to make a US regulatory filing by the end of 2022.
